Bank of New York Mellon Corp Has $40.74 Million Stock Holdings in GSK PLC Sponsored ADR (NYSE:GSK)

Bank of New York Mellon Corp raised its holdings in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 8.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,051,637 shares of the pharmaceutical company's stock after acquiring an additional 77,586 shares during the quarter. Bank of New York Mellon Corp owned 0.05% of GSK worth $40,740,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Brighton Jones LLC purchased a new stake in GSK during the fourth quarter valued at about $528,000. Charles Schwab Investment Management Inc. lifted its stake in GSK by 4.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 126,647 shares of the pharmaceutical company's stock valued at $4,283,000 after buying an additional 5,044 shares in the last quarter. Independent Advisor Alliance lifted its stake in GSK by 13.0% during the fourth quarter. Independent Advisor Alliance now owns 17,050 shares of the pharmaceutical company's stock valued at $577,000 after buying an additional 1,964 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in GSK by 83.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 4,189 shares of the pharmaceutical company's stock valued at $142,000 after buying an additional 1,902 shares in the last quarter. Finally, Mondrian Investment Partners LTD lifted its stake in GSK by 17.6% during the fourth quarter. Mondrian Investment Partners LTD now owns 5,838,384 shares of the pharmaceutical company's stock valued at $205,920,000 after buying an additional 874,004 shares in the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

GSK has been the subject of a number of analyst reports. Wall Street Zen lowered shares of GSK from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. BNP Paribas began coverage on shares of GSK in a research report on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price target for the company. Berenberg Bank reissued a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. Finally, Hsbc Global Res raised shares of GSK to a "strong sell" rating in a research report on Monday, April 28th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $37.38.

GSK Stock Up 1.2%

Shares of NYSE GSK traded up $0.44 during mid-day trading on Wednesday, reaching $38.26. The company had a trading volume of 6,322,981 shares, compared to its average volume of 5,032,958. The stock has a fifty day moving average of $39.00 and a two-hundred day moving average of $37.34. GSK PLC Sponsored ADR has a 12-month low of $31.72 and a 12-month high of $44.67. The company has a market capitalization of $78.34 billion, a price-to-earnings ratio of 19.72, a PEG ratio of 1.53 and a beta of 0.50. The company has a debt-to-equity ratio of 1.21, a quick ratio of 0.58 and a current ratio of 0.87.

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, topping analysts' consensus estimates of $1.08 by $0.05. GSK had a return on equity of 48.82% and a net margin of 9.89%. The firm had revenue of $10.06 billion for the quarter, compared to the consensus estimate of $7.52 billion. During the same quarter in the prior year, the company posted $0.43 earnings per share. The firm's revenue was up 2.1% on a year-over-year basis. As a group, equities research analysts expect that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, July 10th. Investors of record on Friday, May 16th were issued a $0.4216 dividend. The ex-dividend date was Friday, May 16th. This represents a $1.69 dividend on an annualized basis and a yield of 4.41%. This is an increase from GSK's previous quarterly dividend of $0.39. GSK's dividend payout ratio is currently 88.14%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.